எரிகா பீோறிணி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from எரிகா பீோறிணி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In எரிகா பீோறிணி Today - Breaking & Trending Today

DGAP-News: AFFiRiS AG: Positive preclinical in vivo results with AFFiRiS' antibody mAB C6-17 to treat Huntington's disease to be presented at the 16th Annual Huntington's Disease Therapeutics Conference


(0)
DGAP-News: AFFiRiS AG
/ Key word(s): Conference/Study
AFFiRiS AG: Positive preclinical in vivo results with AFFiRiS antibody mAB C6-17 to treat Huntington s disease to be presented at the 16th Annual Huntington s Disease Therapeutics Conference
27.04.2021 / 09:00
Positive preclinical
in vivo results with AFFiRiS antibody mAB C6-17 to treat Huntington s disease to be presented at the 16
th Annual Huntington s Disease Therapeutics Conference
- Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington s disease pathology
- Human mtHTT transgenic mice treated with mAB C6-17 showed significantly reduced mtHTT levels in peripheral organs and central nervous system and displayed improved motor performance ....

United States , Julia Hofmann , Kostenloser Wertpapierhandel , Erica Fiorini , Cornelia Kutzer , Amber Southwell , Mc Services , Division Of Neuroscience , Burnett School Of Biomedical Sciences , Distribution Services , Annual Huntington , Disease Therapeutics Conference , Disease Therapeutics , Chief Technology Officer , Assistant Professor , Burnett School , Biomedical Sciences , Corporate News , Regulatory Announcements , ஒன்றுபட்டது மாநிலங்களில் , ஜூலியா ஹாஃப்மேன் , எரிகா பீோறிணி , ம்ஸீ சேவைகள் , பிரிவு ஆஃப் நரம்பியல் , பர்னெட் பள்ளி ஆஃப் உயிர் மருத்துவ அறிவியல் , விநியோகம் சேவைகள் ,

Positive preclinical in vivo results with AFFiRiS' antibody mAB C6-17 to treat Huntington's ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s .
AFFiRiS AGApril 27, 2021 GMT
Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington’s disease pathology
Human mtHTT transgenic mice treated with mAB C6-17 showed significantly reduced mtHTT levels in peripheral organs and central nervous system and displayed improved motor performance
Results set the ground for AFFiRiS’ potential first-in-class antibody-based systemic therapeutic modalities targeting mtHTT directly
VIENNA, Austria, April 27, 2021 (GLOBE NEWSWIRE) AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific immunotherapies, announces today the presentation of ....

United States , Julia Hofmann , Erica Fiorini , Cornelia Kutzer , Amber Southwell , Mc Services , Division Of Neuroscience , Burnett School Of Biomedical Sciences , Annual Huntington , Disease Therapeutics , Chief Technology Officer , Assistant Professor , Burnett School , Biomedical Sciences , ஒன்றுபட்டது மாநிலங்களில் , ஜூலியா ஹாஃப்மேன் , எரிகா பீோறிணி , ம்ஸீ சேவைகள் , பிரிவு ஆஃப் நரம்பியல் , பர்னெட் பள்ளி ஆஃப் உயிர் மருத்துவ அறிவியல் , ஆண்டு ஹண்டிங்டன் , நோய் சிகிச்சை , தலைமை தொழில்நுட்பம் அதிகாரி , உதவியாளர் ப்ரொஃபெஸர் , பர்னெட் பள்ளி , உயிர் மருத்துவ அறிவியல் ,